VEGFA and glioblastoma: Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor approved for recurrent GBM [13], restricts angiogenesis but provides limited survival improvement due to the blood–brain barrier (BBB) and active efflux mechanisms [14].